Experimental triple therapy takes on Hard-to-Treat Head-Neck cancer
Disease control
Recruiting now
This early-phase trial is testing a new drug called RiMO-301, given as an injection directly into the tumor, along with radiation therapy and an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination is safe and can shrink tumors in people with advanced hea…
Phase: PHASE1, PHASE2 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC